A Study on the Safety and Effectiveness of IBI318 Combined With Conventional TACE (cTACE) as a Perioperative Treatment for Potentially Resected Hepatocellular Carcinoma

PHASE1

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped Due to the company's development strategy adjustment ，Innovent Bioligics decided not to continue the study after consultation with investigators.

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: IBI318
PROCEDURE: cTACE
DRUG: placebo

Sponsor

Innovent Biologics (Suzhou) Co. Ltd.